tbuckley/cabot-search huggingface dataset:
741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
Authors: B. Pothuri, R.W. Naumann, L.P. Martin, D. O'Malley, D. Uyar, J.W. Moroney, J. Diaz, J. Garcia-Donas, A. Redondo Sanchez, A. Gonzalez Martin, D.G. Illescas, L. Liu, C. Berman, A. Oaknin
Journal: Annals of Oncology (2023)
760P Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Authors: A. Qu, J. Wang, Y. Zhuo, Z. Liu, H. Zhu, L. Wei, X. Sun, Y. Gao, H. Cheng, F. Zhao, Y. Song, Q.L. Wen, X. Zhou, P. Wang, J. Yang, L. Zou, X. Yuan, D. Wu, J. He, Y. Zhang
Journal: Annals of Oncology (2023)
690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Authors: M.R. Patel, T. Doi, T. Koyama, G.S. Falchook, C.F. Friedman, S.A. Piha-Paul, M. Gutierrez, M.M. Awad, A.H. Mattour, T. Satoh, N. Okamoto, J. Singh, N. Yoshizuka, M. Qian, X. Qian, B.P. Tran, O. Dosunmu, P. Lu, M.L. Johnson
Journal: Annals of Oncology (2023)
642P A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Authors: J. Cui, N. Chen, C. Pu, L. Zhao, N. Li, C. Wang, Y. Huang, S. Luo, X. Li, Z. Yang, J. Bie, R. Zhu, H. Tang, T. Liang, Y. Wang, V. Lu, Z. Wu, Y. Song, L. Xiao
Journal: Annals of Oncology (2023)
655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)
Authors: B.C. Cho, M.L. Johnson, J. Bar, E. Schaefer, K. Yoh, A. Zer, M.T. Moskovitz, S-H. Lee, V. Moreno Garcia, M.J. De Miguel Luken, Y. Okuma, J-H. Kim, C-H. Lee, P.J. Ansell, C. Biesdorf de Almeida, R. Saab, K. Freise, D. Ramies, E. Jeng, D.R. Camidge
Journal: Annals of Oncology (2023)
656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
Authors: H. Yao, M.H. Ryu, J. Park, M. Voskoboynik, J.H. Kim, K. Liu, M. Barve, A. Acuna-Villaorduna, S-A. Im, A.C. Roy, L-Y. Bai, C-J. Yen, J. Zhang, V. Ganju, L. Wu, M. Yan, L. Bao, Y. Zhao, S. Rong, E. Song
Journal: Annals of Oncology (2023)
662MO Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors
Authors: C-C. Lin, J. Grewal, J.C. Baranda, R.E. Schneider, J. Zhang, L-Y. Bai, Y-M. Yeh, D. Sommerhalder, G. Li, L. Shen, H-C. Hsu, O. Alese, R. Yin, C-Y. Hsieh, S.X. Cai, Y.E. Tian, H. Xia, B. Li, M. Zhang, C. Zhang
Journal: Annals of Oncology (2023)
658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
Authors: Q. Zhou, Y-L. Wu, J. Li, A. Liu, J. Cui, Y. Kuboki, N. Yamamoto, S-W. Han, G. Lin, J-M. Sun, L. Wu, Z. Zhu, J. Shuang, F. Qiu, W. Shi
Journal: Annals of Oncology (2023)
660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
Authors: C.A. Perez, J.T. Henry, N. Lakhani, J.A. Call, E.P. Hamilton, G. Colon-Otero, J.R. Diamond, B. O’Neil, A. Kalyan, G.P. Sonpavde, I. Moreno Candilejo, A.A. Awan, E. Fontana, P. Xu, F. Zhang, N. Nazarenko, A. Patnaik
Journal: Annals of Oncology (2023)
638P Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Authors: Y. Chen, K. Wang, Z. Zhiyuan, H. Zhang, W. Yang, R. Wu, M. Zhou, Z. Zhang, F. Xia
Journal: Annals of Oncology (2023)
669P Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Authors: H. Kang, L.E. Raez, Y. Ohe, M. Khanal, K. Wang, Y. Han, S. Szymczak, S. Barker, A.M. Gilligan
Journal: Annals of Oncology (2023)
646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Authors: A. Hendifar, D.R. Spigel, A. Basu-Mallick, D. Richards, M. Fakih, J. Boles, M. Gupta, K. Chung, A. Cohn, A. Espinosa, K.C. Hourdequin, K. Johnson, J.M. Michalski, J.G. Misleh, S. Mukkamala, A.S. Paulson, S. Ratnam, S.H. Shao, R. Wasserman, L.S. Rosen
Journal: Annals of Oncology (2023)
634P The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Authors: M. Michael, R. Wong, S. Gill, A. Strickland, N. Pavlakis, J. Shapiro, E. Link, M. Farrell, S. Ngan, A. Heriot, D. Goldstein, C. Mitchell, K. Wilson, M. Mui, R. Ramsay, E. Segelov
Journal: Annals of Oncology (2023)
666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Authors: S. Lu, F.G.M. De Braud, Y. Fan, X. Hu, Y. Ohe, Y. Yu, M-J. Ahn, P. Cassier, J.J. Lin, L. Paz-Ares, C. Xue, W. Bordogna, S. Patel, H. Zeuner, X. Dong
Journal: Annals of Oncology (2023)
631P Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Authors: G. Maddalena, F.A. Zeineddine, S. Chowdhury, M. Zeineddine, A. Yousef, M.J. Overman, E.S. Kopetz, J.P.Y-C. Shen
Journal: Annals of Oncology (2023)
680P First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Authors: K. Moore, M.R. Patel, G.S. Falchook, E. Fontana, B. Bashir, C.A. Perez, M. Barve, S. Ulahannan, H. Milward, A. Fielding, B. Harrop, N. Little, T. Coleman, A. Wilby, S. Busacca, S. Holt, S. Menon, D. Headley, I. Smith, M.L. Johnson
Journal: Annals of Oncology (2023)
636P Combination therapy of envafolimab, suvemcitug, and FOLFIRI in patients with metastatic microsatellite stable (MSS) or mismatch-repair proficient (pMMR) colorectal cancer: Results from a phase II clinical trial
Authors: Y. Liu, J. Wang, Y. Fang, Y. Deng, C. Hu, Q. Fan, K. Gu, Y. Zhang, C. Yang, J. Tian, Z. Liu, X. Sun, S. Sun, Y. Cheng
Journal: Annals of Oncology (2023)
664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Authors: R.B. Corcoran, K.T. Do, J. Cleary, A. Parikh, O. Yeku, C.D. Weekes, L. Ahronian, G. Mauri, J. Tian, J. Brugge, D. Juric, K.T. Flaherty, R.J. Sullivan, J. Clark, R. Heist, U.A. Matulonis, J.F. Liu, G.I. Shapiro
Journal: Annals of Oncology (2023)
672P Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Authors: R. Dziadziuszko, I. Lugowska, E. Garralda, K.I. Rojas Laimito, T. Rzymski, R. Dudziak, P. Littlewood, H. Nogai, V. Boni, J. Fuentes Antras, G. Alonso, O. Saavedra Santa Gadea, R. Kuklík
Journal: Annals of Oncology (2023)
625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Authors: C. Gallois, M.E. Elez Fernandez, E. Auclin, E.S. Bergen, S. Pernot, J. Higué, I. Trouilloud, Y. Touchefeu, A. Turpin, T. Mazard, L. Pilla, S. Cuissy, V. Wookey, A. Perret, C. Melchior, P. Artru, S. Stintzing, O. Dubreuil, D. Tougeron, J. Taieb
Journal: Annals of Oncology (2023)
661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
Authors: T.W. Kim, J. Lee, S.J. Shin, S-W. Han, Y.J. Kim, J-S. Kim, S.Y. Oh, D.H. Lee, M.H. Kim, S.T. Kim, Y. Hong, S. Kim, T. Kim, B. Lee, J. Eng-Wong, Y. Yan, C. Chou, Y.S. Noh
Journal: Annals of Oncology (2023)
635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Authors: M. van den Eynde, N. Huyghe, I. Sinapi, A. De Cuyper, E. Verstraelen, P. Goffette, B. Ghaye, M. Papier, D. Bedognetti, A. van Maanen, M-L. Castella, J. Galon, J. Carrasco
Journal: Annals of Oncology (2023)
659MO Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
Authors: J. Zhang, R. Liu, S. Gao, X. Li, J. Chen, X. Yao, None Y. fang, R. Li, M. Zhang, F. Qiu, Y. Li, T. Liu, H. Huang, X. Zhang, H. Guo, B. Hu, J-Y. Liu, Q. Yang, P. Zhao, P. Wang
Journal: Annals of Oncology (2023)
665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Authors: J. Heymach, N. Kotecki, H. Prenen, G. Alonso, C.R. Lindsay, M. Barve, C. Thamer, S. Eigenbrod-Giese, M.A. Marotti, G. Van Lancker
Journal: Annals of Oncology (2023)
685P BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Authors: E. Song, H. Yao, Y. Wang, Y. Zeng, M.L. Sun, H. Zong, R. Lin, None Z. wen, R.M. Ding, J. Yu, S. Xiao, H. Wang, H. Zhu, M.S. Olivo, Y. Zhu
Journal: Annals of Oncology (2023)
628P Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Authors: A. Stemmer, O. Margalit, V. Serpas, G.Z. Strauss, J. Thomas, P. Shash, K. Levanon, E. Shacham Shmueli, E.S. Kopetz, M.J. Overman, B. Boursi
Journal: Annals of Oncology (2023)
647P Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Authors: G. Rizzo, S.E. Pineda Chavez, M. Wozny, C. Cappadona, A. Maroli, P. Spaggiari, M. Carvello, R. Asselta, E. Casiraghi, G. Valentini, A. Repici, A. Spinelli, A. Armuzzi, S. Vetrano
Journal: Annals of Oncology (2023)
683P Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Authors: Y. Shan, R. Liu, G. Song, H. Song, J. Jiang, C. Jia, X. Huang, X. Yuan, W-J. Yang, X. Wang, Q. Wang, C. Hu, C. Zhao, Q. Wang, J. Zhu
Journal: Annals of Oncology (2023)
640P A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results
Authors: J. Hubbard, D. Ahn, J.C. Jones, Z. Jin, M. Zhu, H. Xie, E. Novo, R. Graham, K. Wittenberger, M. Kremlitzka, Z. Csiszovszki, E. Somogyi, O. Lorincz, L. Molnar, J. Toth, H. Youssoufian, E.R. Toke
Journal: Annals of Oncology (2023)
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Authors: K.C. Arbour, S. Punekar, I. Garrido-Laguna, D.S. Hong, B. Wolpin, M.S. Pelster, M. Barve, A. Starodub, D. Sommerhalder, S. Chang, Y. Zhang, Z. Salman, X. Wang, C. Gustafson, A.I. Spira
Journal: Annals of Oncology (2023)
629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Authors: D. Tougeron, V. Hautefeuille, A. Zaanan, K. Le Malicot, V. Moulin, R. Cohen, T. Lecomte, A. Aleba, J. Viaud, Y.H. Lam, P.L. Etienne, L. Mosser, M. Ramdani, S. Le Sourd, C. Poisson Ligeza, G. Goujon, C. Lepage, O. Bouche
Journal: Annals of Oncology (2023)
657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
Authors: B.T. Li, K-W. Lee, M. Pegram, M.R. Sharma, J. Lee, A.I. Spira, Y-K. Kang, K.N. Moore, D. Rasco, G.J. Hanna, B.A. Weinberg, T. Yu, M. Alonso, J. Ptacek, M. Yin, C. Tapia, L. Xu, E.A. Perez, E.E. Dumbrava
Journal: Annals of Oncology (2023)
670P Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Authors: P. Zhang, J. Gong, H. Guo, W. Han, B. Cao, J. Zhang, Z. Niu, Y. Cheng, C. He, J. Fan, P. Peng, C. Sun, H. Wang, Y. Yu, Y. Zhu, Y. Wu, Q. Li, P. Huang, F. Wu, L. Shen
Journal: Annals of Oncology (2023)

Tinengotinib is a spectrum-selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology pathways by inhibiting Aurora kinases A/B, Janus kinases and receptor tyrosine kinases (FGFRs and VEGFRs). Tinengotinib has shown promising clinical signal in solid tumors from several studies globally. Here we present the interim data from a phase Ib/II trial in China. Pts with advanced/metastatic solid tumors were enrolled and treated with tinengotinib in 21-day cycle. Monotherapy and combination therapy with dose escalation (phase Ib) and dose expansion (phase II) were designed. As of 5-Mar-2023, thirty-three (33) pts have received tinengotinib monotherapy. Median age was 58.0 years (29-81), 66.7% were male, 81.8% had ECOG of 1, 87.9% had stage IV disease, 69.7% had ≥3 lines of prior therapies. No DLT was observed in phase Ib (3 pts in each group of 8, 10, 12 mg QD). 10 mg QD was selected as RP2D. Treatment-related AEs (TRAEs) were reported in 30 (90.9%) pts, Gr 3 in 14 (42.4%), Gr 4 in 1 (3.0%), and no Gr 5. The most common TRAEs (≥30%) included abnormal laboratory parameters (blood thyroid stimulating hormone increased, white blood cell count decreased, neutrophil count decreased, aspartate aminotransferase increased, alanine aminotransferase increased), palmar-plantar erythrodysaesthesia syndrome and anaemia. Among 22 efficacy-evaluable pts, the median Progression-free survival (PFS) have reached 6.70 (95% CI, 3.22-NA) months. For 19 pts with measurable target lesions, the overall response rate (ORR) and disease control rate (DCR) were 15.8% and 89.5%, respectively. For 4 CCA pts harboring FGFR2 alteration, ORR was 50%, DCR was 100%. One responder with prior treatment of erdafitinib achieved tumor reduction of 44%, the other with no prior FGFR inhibitor treatment achieved 69% reduction. Tinengotinib monotherapy was well-tolerated in Chinese pts and 10 mg QD was selected as RP2D. Promising efficacy has been observed, especially in CCA with FGFR2 alteration. The ongoing study is to further evaluate the safety and efficacy of monotherapy and combination therapy.
675P A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Authors: J. Yu, Y. Sun, S. Guo, H.Q. Wang, J. Wu, X. Jiang, J. Chen, G. Yang, C. Yang
Journal: Annals of Oncology (2023)
630P Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Authors: R. Barbe, Y. Belkouchi, C. David, L. Lawrance, S. Harguem-Zayani, J. Hadchiti, L. Dawi, M. Kind, F. Selhane, S. Ammari, Y.M. Menu, I. Hoferer, A. Bertin, B. Cervantes, C. Balleyguier, None H. talbot, P-H. Cournede, R. Cohen, T. André, N. Lassau
Journal: Annals of Oncology (2023)
671P Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Authors: S. Goel, M. Provencio Pulla, M.J. De Miguel Luken, M. Ghalib, V. Calvo de Juan, M.B. Hammami, S. Vikash, R. Maitra, I. Chaudhary, S. Martinez, C. Kahatt, S. Extremera, S. Fudio, A. Zeaiter
Journal: Annals of Oncology (2023)
637P A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for advanced Colorectal Cancer Liver Metastases (CRLM)
Authors: L. Wang, T. Zhang, None Y. zhao, Q. Pan, None A. mao, W. Zhu, Y. Feng, J. Zhou
Journal: Annals of Oncology (2023)
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Authors: B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito, S. Siena, P.G. Aftimos, I. Anderson, G. Curigliano, M.J. De Miguel Luken, M. Kalra, D-Y. Oh, J.O. Park, S. Postel-Vinay, S.Y. Rha, T. Satoh, I. Spanggaard, F. Michelini, A. Smith, K. Kalil Machado, C. Saura Manich
Journal: Annals of Oncology (2023)
632P Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Authors: S. Meltzer, J.P. Berg, H.M. Hamre, C. Kersten, E. Hofsli, M.G. Guren, H. Sorbye, K. Flatmark, A.H. Ree
Journal: Annals of Oncology (2023)
645P A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Authors: V. Florou, H. Lee, C.D. Nevala-plagemann, H.P. Soares, G.W. Gilcrease, J. Whisenant, K. Barber, K. Boucher, I. Garrido-Laguna
Journal: Annals of Oncology (2023)
641P Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Authors: F. Pietrantonio, F. Morano, M. Niger, F. Ghelardi, C. Chiodoni, M. Palazzo, N. Brambilla, E. Benincasa, G. Giacovelli, C. Vitalini, F. Girolami, L.C. Rovati
Journal: Annals of Oncology (2023)
673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Authors: P. Schoeffski, P. Lorusso, N. Yamamoto, I. Lugowska, V. Moreno Garcia, U. Lauer, C. Hu, G. Jayadeva, M. Lahmar, M. Gounder
Journal: Annals of Oncology (2023)
679P Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Authors: I. Moreno, T. Hernandez, E. Calvo, S. Fudio, C. Kahatt, S. Martinez, J. Iglesias, R.O. Calafati, L. Pérez Ramos, L. Montilla, A. Zeaiter, R. Lubomirov
Journal: Annals of Oncology (2023)
684P Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Authors: J. Li, S. Luo, T. Liu, L. Dong, X. Yuan, J. Feng, Y. Wang, Y. Deng, J. Chen, M. Zhang, H. Zhou, Y. Cao, W. Qiu, X. Ren, S. Cai, Y. Dong, W. Wang, Y. Shen, N. Dou, C. Huang
Journal: Annals of Oncology (2023)
677P Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Authors: Y.B. Sang, Y. Kim, M.A. Lee, S.Y. Rha, M. Jung, C-K. Lee, Y.H. Park, D. Heo, A. Kim, J. Kim, J-H. Kim
Journal: Annals of Oncology (2023)
676P Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Authors: R. Clift, S. Richardson, T. Ehara, H. Yanagida, I. Hung, Z. Amso, K. Salvador, M. Guest, G. Han, A. Bhat, D. Cole, E. Bischoff, G. Li
Journal: Annals of Oncology (2023)
667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Authors: D.S. Hong, R-H. Xu, R.S. McDermott, L. Shen, M.P. Dierselhuis, F. Doz, M. Tahara, V. Bernard-Gauthier, R. Norenberg, N. Brega, T.W. Laetsch, A. Drilon
Journal: Annals of Oncology (2023)
653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
Authors: J. Wang, J. Zhao, J. Zhong, X. Li, J. Fang, Y. Yu, X. Li, X. Fang, J. Chang, Z. Liu, Y. Zhao, Q. Song, C. Bai, A. Wang-Gillam, Y. Ding, Z. Rao, C. Bi
Journal: Annals of Oncology (2023)
643P A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Authors: Y. Cha, S-W. Song, J.Y. Choi, Y.W. Park, H. Lee, S. Lee, M.A. Lee, J. Lee
Journal: Annals of Oncology (2023)
663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Authors: C. Rojas, I. Lugowska, R. Juergens, A. Sacher, S. Weindler, M.A.N. Sendur, R. Dziadziuszko, A. Pal, E. Castanon Alvarez, E.S. Ahern, N. Lakhani, L-C. Chen, T. Jemielita, Y.S. Choi, A. Stathis
Journal: Annals of Oncology (2023)
668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Authors: A. Drilon, L. Shen, C. van Tilburg, F. Doz, D.S.W. Tan, J.J. Lin, S. Kummar, U.N. Lassen, R.S. McDermott, M.P. Dierselhuis, C.M. Albert, R. Nagasubramanian, T. Watt, T. Patil, D-I. Burcoveanu, R. Norenberg, N. Brega, T.W. Laetsch, R-H. Xu, D.S. Hong
Journal: Annals of Oncology (2023)
682P Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)
Authors: A. Drilon, I.I. Rodriguez Rivera, A.I. Spira, M.R. Sharma, R. Hansen, S. Chowdhry, S. Kasibhatla, A. Tewari, S. Weymer, K. Wagner, T.A. Yap
Journal: Annals of Oncology (2023)
533P Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Authors: M.A. Vaz Salgado, J. Earl, J.M. Sepulveda Sanchez, Y. Ruano, J. Gutierrez, H. Pian, L.L. Ley, M.L. Villamayor Delgado, A. Carrato Mena, E. Fernandez, M. Martin, R. Ferreiro Monteagudo, F. Longo Muñoz, M. Rodriguez, V. Albarrán, J. Pozas Perez, P. Alvarez Ballesteros, M.V. San Roman Gil, None A.H. lain
Journal: Annals of Oncology (2023)
526P In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Authors: C. Saiz-Ladera, J. Bartolome, A. Manzano Fernández, S. Cabezas-Camarero, G. Velasco, P. Pérez Segura, A. Ocana Fernandez
Journal: Annals of Oncology (2023)
530P Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Authors: P. Anuradha, S. Papaiah Susheela, P. Damodara, S. Hegde, S. Suresh, R. Ghosh, S.S. Gopireddy, R. Krishnappa, R. Naik, S. Belagutti Jayappa, V. Gupta, S. Chiradoni Thungappa, S. Revannasiddaiah, M. Hamid, S. Gopal, S. Rudrappa, M. HV, V. NK, K. Kallur, S. Patil
Journal: Annals of Oncology (2023)
521P Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Authors: A.B. Diaz Mendez, M. Di Giuliani, A. Sacconi, G. Regazzo, S. Ramponi, G. Blandino, C. Garufi, M.G. Rizzo
Journal: Annals of Oncology (2023)
537P S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Authors: A. Steindl, A. Kienzle, E. Tomasich, J.M. Berger, C. Englisch, L. Gottmann, M. Korpan, M. Kleinberger, A.M. Starzer, B. Kiesel, G. Widhalm, F. Eckert, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2023)
535P Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Authors: C.M. Martín Abreu, R. Sun, S.N. Dumont, M-S. Minot This, T. Grinda, N. Epaillard, D. Guyon, G. Garcia, J. Pallud, E. Dezamis, N. Aghakhani, M. Bouchaala, C. Adam, R. Saffroy, P. Varlet, A. Tauziede-Espariat, I. Issoufaly, I. Benchara, F. Dhermain, S. Bockel
Journal: Annals of Oncology (2023)
534P Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Authors: T. Pacheco, M. Müller, D.D.C.M.E.S. Delgado, A.N. de Abrunhosa Branquinho, A. Figueiredo, L.A. Marques Da Costa, M.L. Albuquerque
Journal: Annals of Oncology (2023)
528P Progression risk after pregnancy in patients with glioma
Authors: A. Leibetseder, M. Mair, M. Aichholzer, G. Widhalm, F. Eckert, A. Wöhrer, S. Weis, R. Helbok, M. Preusser, J. Pichler, A.S. Berghoff
Journal: Annals of Oncology (2023)